Optimi Health Corp. announced a series of milestones in its international psychedelic supply operations and corporate marketing strategy. Optimi has completed its first international shipment to Israel of its in-house manufactured MDMA active pharmaceutical ingredient (API) to the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV).

This achievement, made possible through the grant of the necessary Export Permit from Health Canada, marks a pivotal step in Optimi's mission to support global psychedelic research and innovation. Through the export process, Optimi has also received the CERS (Canadian Export Reporting System) and CBSA (Canada Border Services Agency) Exporters Authorization ID, further confirming its capacity to export controlled substances from Canada. This authorization is crucial for maintaining compliance with international trade regulations and ensuring smooth logistics for future shipments to customers around the world.